Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy

被引:12
作者
Sulsenti, Roberta [1 ]
Jachetti, Elena [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Mol Immunol Unit, I-20133 Milan, Italy
关键词
mast cells; cancer; immunotherapy; tumor microenvironment; TUMOR-NECROSIS-FACTOR; MARKED SURVIVAL ADVANTAGE; T-CELL; INTRATUMORAL INJECTION; TARGETED DELIVERY; PROSTATE-CANCER; CLINICAL-TRIAL; FACTOR-ALPHA; TNF-ALPHA; IFN-GAMMA;
D O I
10.3390/pharmaceutics15061692
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tumor development, progression, and resistance to therapies are influenced by the interactions between tumor cells and the surrounding microenvironment, comprising fibroblasts, immune cells, and extracellular matrix proteins. In this context, mast cells (MCs) have recently emerged as important players. Yet, their role is still controversial, as MCs can exert pro- or anti-tumor functions in different tumor types depending on their location within or around the tumor mass and their interaction with other components of the tumor microenvironment. In this review, we describe the main aspects of MC biology and the different contribution of MCs in promoting or inhibiting cancer growth. We then discuss possible therapeutic strategies aimed at targeting MCs for cancer immunotherapy, which include: (1) targeting c-Kit signaling; (2) stabilizing MC degranulation; (3) triggering activating/inhibiting receptors; (4) modulating MC recruitment; (5) harnessing MC mediators; (6) adoptive transferring of MCs. Such strategies should aim to either restrain or sustain MC activity according to specific contexts. Further investigation would allow us to better dissect the multifaceted roles of MCs in cancer and tailor novel approaches for an "MC-guided" personalized medicine to be used in combination with conventional anti-cancer therapies.
引用
收藏
页数:16
相关论文
共 140 条
[41]   Mast cells are an essential hematopoietic component for polyp development [J].
Gounaris, Elias ;
Erdman, Susan E. ;
Restaino, Clifford ;
Gurish, Michael F. ;
Friend, Daniel S. ;
Gounari, Fotini ;
Lee, David M. ;
Zhang, Guoying ;
Glickman, Jonathan N. ;
Shin, Kichul ;
Rao, Varada P. ;
Poutahidis, Theofilos ;
Weissleder, Ralph ;
McNagny, Kelly M. ;
Khazaie, Khashayarsha .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (50) :19977-19982
[42]   Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours [J].
Gregorc, V. ;
Santoro, A. ;
Bennicelli, E. ;
Punt, C. J. A. ;
Citterio, G. ;
Timmer-Bonte, J. N. H. ;
Cappio, F. Caligaris ;
Lambiase, A. ;
Bordignon, C. ;
van Herpen, C. M. L. .
BRITISH JOURNAL OF CANCER, 2009, 101 (02) :219-224
[43]   CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction [J].
Gri, Giorgia ;
Piconese, Silvia ;
Frossi, Barbara ;
Manfroi, Vanessa ;
Merluzzi, Sonia ;
Tripodo, Claudio ;
Viola, Antonella ;
Odom, Sandra ;
Rivera, Juan ;
Colombo, Mario P. ;
Pucillo, Carlo E. .
IMMUNITY, 2008, 29 (05) :771-781
[44]   Mast Cell Tryptase Contributes to Pancreatic Cancer Growth through Promoting Angiogenesis via Activation of Angiopoietin-1 [J].
Guo, Xiangjie ;
Zhai, Liqin ;
Xue, Ruobing ;
Shi, Jieru ;
Zeng, Qiang ;
Gao, Cairong .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (06)
[45]   Molecular targets on mast cells and basophils for novel therapies [J].
Harvima, Ilkka T. ;
Levi-Schaffer, Francesca ;
Draber, Petr ;
Friedman, Sheli ;
Polakovicova, Iva ;
Gibbs, Bernhard F. ;
Blank, Ulrich ;
Nilsson, Gunnar ;
Maurer, Marcus .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (03) :530-544
[46]   Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma [J].
Hedstrom, Gustaf ;
Berglund, Mattias ;
Molin, Daniel ;
Fischer, Marie ;
Nilsson, Gunnar ;
Thunberg, Ulf ;
Book, Majlis ;
Sundstrom, Christer ;
Rosenquist, Richard ;
Roos, Goran ;
Erlanson, Martin ;
Amini, Rose-Marie ;
Enblad, Gunilla .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (01) :68-71
[47]   The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity [J].
Hemmerle, T. ;
Probst, P. ;
Giovannoni, L. ;
Green, A. J. ;
Meyer, T. ;
Neri, D. .
BRITISH JOURNAL OF CANCER, 2013, 109 (05) :1206-1213
[48]   Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes [J].
Hempel Sullivan, Heidi ;
Maynard, Janielle P. ;
Heaphy, Christopher M. ;
Lu, Jiayun ;
De Marzo, Angelo M. ;
Lotan, Tamara L. ;
Joshu, Corinne E. ;
Sfanos, Karen S. .
JOURNAL OF PATHOLOGY, 2021, 253 (04) :415-426
[49]   The Tumor Microenvironment Innately Modulates Cancer Progression [J].
Hinshaw, Dominique C. ;
Shevde, Lalita A. .
CANCER RESEARCH, 2019, 79 (18) :4557-4566
[50]   PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity [J].
Hirano, Tomoko ;
Honda, Tetsuya ;
Kanameishi, Shuto ;
Honda, Yuki ;
Egawa, Gyohei ;
Kitoh, Akihiko ;
Nakajima, Saeko ;
Otsuka, Atsushi ;
Nomura, Takashi ;
Dainichi, Teruki ;
Yaguchi, Tomonori ;
Inozume, Takashi ;
Kataoka, Tatsuki R. ;
Tamada, Koji ;
Kabashima, Kenji .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 148 (02) :563-+